Biostatistics & Population Health

DALYs and QALYs in burden-of-disease analysis

Clinical Overview and When to Suspect Burden-of-Disease Metric Misuse

— DALY: years of healthy life lost — a negative metric. Lower is better.

— QALY: years of healthy life gained or lived — a positive metric. Higher is better.

— A health department, ministry of health, WHO, or Global Burden of Disease (GBD) report

— Cost-effectiveness analysis (CEA) with a denominator of "per QALY gained" or "per DALY averted"

— Comparison of two interventions where outcomes differ in both quantity (lifespan) and quality (morbidity) of life

— Allocation of scarce resources, vaccine prioritization, or screening program justification

Board pearl: If a question stem provides cost data and a health outcome that has both a survival and a quality-of-life component, the correct analytic framework is almost always cost-utility analysis using QALYs (in the US/HHS context) or cost-effectiveness using DALYs averted (in WHO/global health context). Choosing crude mortality reduction or life-years-saved as the denominator is the classic distractor — it ignores morbidity and undervalues interventions for chronic disabling disease.

DALYs (Disability-Adjusted Life Years) and QALYs (Quality-Adjusted Life Years) are the two dominant summary measures of population health used in burden-of-disease analysis, cost-effectiveness research, and health policy decision-making.

On Step 3, suspect a DALY/QALY question whenever the stem mentions:

Both metrics integrate mortality and morbidity into a single composite — this is their core utility versus crude mortality rate or life expectancy alone.

Step 3 expects you to recognize that a 60-year-old who survives stroke with hemiplegia contributes both YLL (if she dies early) and YLD (years lived with disability) — crude mortality misses the disability burden entirely.

Presentation Patterns and Key History — How DALY/QALY Questions Appear

— 5 × 0.6 = 3.0 QALYs vs 2 × 1.0 = 2.0 QALYs → first intervention preferred.

Key history features in vignettes:

— Mention of utility weights (0 = death, 1 = perfect health) → QALY framework

— Mention of disability weights (0 = perfect health, 1 = death — inverted) → DALY framework

— Mention of a discount rate (typically 3%) → cost-effectiveness analysis context

— Mention of an ICER threshold ($50,000–$150,000/QALY in US) → cost-utility decision rule

Key distinction: Utility weights (QALY) and disability weights (DALY) run in opposite directions on the 0–1 scale. A test-taker who confuses them will invert every calculation. Memorize: QALY weight = "how good is this year"; DALY weight = "how bad is this disability."

Pattern 1 — The policy stem: "A state health commissioner must choose between funding program A (HPV vaccination) or program B (colorectal cancer screening). Which metric best compares them?" → QALY-based cost-utility analysis.

Pattern 2 — The global health stem: "WHO is comparing malaria control versus maternal mortality reduction in sub-Saharan Africa." → DALYs averted per dollar spent.

Pattern 3 — The calculation stem: A specific intervention extends life by 5 years at 0.6 utility versus 2 years at full health — calculate QALYs gained.

Pattern 4 — The composition stem: "DALY = ?" → YLL + YLD (Years of Life Lost + Years Lived with Disability).

Pattern 5 — The interpretation stem: Reading a GBD figure showing ischemic heart disease as the top global DALY contributor, with low back pain dominating YLDs but contributing minimally to YLLs.

Physical Exam Findings — Conceptual "Exam" of the Metrics

— YLL (Years of Life Lost) = (expected life expectancy at age of death) − (actual age at death), summed across deaths.

— YLD (Years Lived with Disability) = (prevalence or incidence of condition) × (disability weight) × (duration).

— DALY = YLL + YLD.

— Reference life expectancy traditionally drawn from a standard life table (GBD uses ~86 years for both sexes in current iterations).

— QALY = Σ (time in health state × utility weight of that state).

— Utility weights derived from instruments: EQ-5D, SF-6D, HUI, or direct elicitation (standard gamble, time trade-off).

— A year in perfect health = 1 QALY; a year dead = 0 QALY; states worse than death can have negative utilities (rare but valid).

Board pearl: If a stem asks why a childhood vaccination program looks less cost-effective than expected, the answer is often discounting of future QALYs gained — benefits 60 years downstream are heavily attenuated at a 3% annual rate.

Since DALYs and QALYs are analytic constructs, the "physical exam" equivalent is dissecting the structural anatomy of each metric.

DALY anatomy:

QALY anatomy:

Hemodynamic analogy: Think of DALYs as "cardiac output of lost health" — they capture both stroke volume (severity of disability) and heart rate (number of people affected and duration).

Discounting: Both metrics typically apply a 3% annual discount rate to future health, reflecting time preference. Step 3 may test that discounting reduces the apparent benefit of prevention programs whose payoff is decades away.

Age weighting: Older GBD methodology weighted prime working-age years more heavily; current GBD (post-2010) no longer applies age weights — all life-years are equal.

Diagnostic Workup — Calculating DALYs Step by Step

— Identify deaths attributable to the condition in a defined time window (usually 1 year).

— For each death: YLL = standard life expectancy at age of death − age of death.

— Example: 100 deaths at age 65, standard LE at 65 = 21 years → YLL = 100 × 21 = 2,100 YLL.

— Identify number of prevalent cases (or incident cases × duration).

— Multiply by the disability weight for that health state (published GBD weights: e.g., mild diabetes ~0.05, severe with complications ~0.20).

— Example: 50,000 cases × 0.10 average weight × 1 year = 5,000 YLD.

Common calculation traps on Step 3:

— Forgetting that YLD uses prevalence × disability weight × duration, not just count.

— Using age at onset instead of age at death for YLL.

— Confusing disability weight (DALY) with utility weight (QALY) — they sum to 1: utility + disability = 1 in many simple models.

Step 3 management: When a stem provides raw mortality and morbidity data and asks for the total burden, methodically compute YLL and YLD separately, then add. Skipping YLD systematically undervalues chronic non-fatal conditions like depression, low back pain, and migraine — all top-10 global YLD contributors.

Step 1 — Define the condition and population: e.g., type 2 diabetes in adults aged 40–70 in a city of 1 million.

Step 2 — Quantify YLL:

Step 3 — Quantify YLD:

Step 4 — Sum: DALY = YLL + YLD = 2,100 + 5,000 = 7,100 DALYs.

Step 5 — Apply discounting if comparing across time horizons (typically 3%/year).

Step 6 — Report per 100,000 population for comparability: 7,100 / 1,000,000 × 100,000 = 710 DALYs per 100,000.

Diagnostic Workup — QALY Calculation and Cost-Effectiveness Mechanics

— For each health state over time, multiply duration × utility weight, then sum.

— Example: Patient lives 3 years at utility 0.8 (post-MI on optimal medical therapy), then 2 years at 0.5 (heart failure), then dies. QALYs = (3 × 0.8) + (2 × 0.5) = 2.4 + 1.0 = 3.4 QALYs.

— ICER = (Cost_new − Cost_standard) / (QALY_new − QALY_standard).

— Reported in $/QALY gained.

— Example: New drug costs $40,000 more and yields 0.8 additional QALYs → ICER = $50,000/QALY.

— < $50,000/QALY: highly cost-effective (historical benchmark)

— $50,000–$150,000/QALY: cost-effective (modern range, ICER Institute uses this band)

— > $150,000/QALY: generally not cost-effective

— WHO uses 1–3× per capita GDP/DALY averted as a rough threshold internationally.

— NE (more costly, more effective) → use ICER vs threshold

— SE (less costly, more effective) → dominant, adopt

— NW (more costly, less effective) → dominated, reject

— SW (less costly, less effective) → use ICER cautiously (cost-saving but harmful)

Key distinction: Cost-effectiveness analysis (CEA) uses natural units (life-years, cases prevented). Cost-utility analysis (CUA) uses QALYs, allowing comparison across diseases. Cost-benefit analysis (CBA) monetizes outcomes in dollars. Step 3 stems comparing across different conditions require CUA (QALYs), not CEA.

QALY calculation:

Incremental Cost-Effectiveness Ratio (ICER):

Willingness-to-pay (WTP) thresholds (US convention):

Cost-effectiveness plane quadrants:

Sensitivity analysis (one-way, probabilistic) tests robustness of ICER to parameter uncertainty — commonly visualized on cost-effectiveness acceptability curves.

Risk Stratification — Choosing Between DALYs and QALYs

— Operating in a high-income country health system (US, UK NICE, Canada CADTH).

— Conducting cost-utility analysis for drug formulary, coverage, or reimbursement decisions.

— Patient-level decision aids and shared decision-making (utilities from patient preferences).

— Comparing interventions that improve both length and quality of life.

— Conducting global burden of disease comparisons (WHO, GBD).

— Low/middle-income country health planning where preference-based utilities are scarce.

— Comparing disease burdens rather than intervention effects.

— Public health priority-setting at population scale.

— DALYs traditionally used age-weighting (deprecated in GBD 2010+) and discounting; QALY conventions vary by agency.

— DALYs anchor to a normative standard life expectancy; QALYs anchor to observed survival.

— DALYs treat death as 0 health; QALYs allow states worse than death (negative utilities).

— May systematically undervalue health of the elderly and disabled.

— Disability weights derived from general population surveys may not match lived experience of patients with the condition.

— Ethical concerns about using utility/disability weights for resource allocation (Oregon Medicaid controversy is a classic example).

Board pearl: A stem set in the US (CMS, USPSTF, ICER) almost always wants QALYs. A stem set in WHO, low-income, or global comparison contexts wants DALYs. Match the metric to the institutional setting.

Use QALYs when:

Use DALYs when:

Conceptual symmetry: In many simple models, 1 QALY gained ≈ 1 DALY averted (utility 0.8 = disability 0.2; gaining a year at utility 0.8 ≈ averting 0.2 DALYs of disability burden).

Asymmetries that matter:

Critiques common to both:

Pharmacotherapy Analogy — QALY-Based Drug Evaluation

— Standard chemotherapy: median survival 12 months at utility 0.6 → 0.6 QALYs.

— New immunotherapy: median survival 24 months at utility 0.7 → 1.4 QALYs.

— Incremental QALYs = 1.4 − 0.6 = 0.8 QALY.

— Incremental cost = $120,000.

— ICER = $120,000 / 0.8 = $150,000/QALY — at the upper edge of US WTP.

— Statins for primary prevention: ICERs typically <$50,000/QALY in moderate/high-risk patients — highly cost-effective.

— PCSK9 inhibitors (evolocumab, alirocumab): early ICERs >$300,000/QALY drove price reductions to reach acceptable thresholds.

— Direct-acting antivirals (DAAs) for HCV: high upfront cost but durable cure → very favorable long-term QALY profile.

— Hospice and palliative care: paradoxically cost-effective by reducing costly futile care while modestly improving end-of-life utility.

— Vaccines (HPV, pneumococcal, RSV): nearly always cost-effective or cost-saving due to broad prevention.

— Markov models with health states and transition probabilities — workhorse for chronic disease.

— Decision trees for short-horizon acute interventions.

— Microsimulation for individual-level heterogeneity.

Step 3 management: When a formulary committee asks whether to add a new drug, the proper framework is the ICER versus a societal WTP threshold ($100,000–$150,000/QALY in the US). A drug with an ICER of $500,000/QALY should generally be rejected or price-negotiated regardless of its biological efficacy.

Cost-utility analysis is the dominant framework for evaluating new pharmaceuticals in modern formulary decisions.

Worked example — novel oncology drug:

Drug classes commonly tested in QALY frameworks on Step 3:

Pharmacoeconomic modeling techniques:

Advanced Methodology — Utility Elicitation and Disability Weights

— Standard gamble (SG): patient chooses between certain health state X and a gamble between perfect health (probability p) and death (1−p). Utility = p at indifference. Theoretically the gold standard under expected utility theory.

— Time trade-off (TTO): patient trades years in poor health for fewer years in perfect health. Utility = (years in perfect health) / (years in poor health).

— Visual analog scale (VAS): direct rating from 0–100. Simpler but biased.

— Multi-attribute utility instruments: EQ-5D-5L (5 domains: mobility, self-care, usual activities, pain, anxiety/depression), SF-6D, HUI3. EQ-5D is the NICE-mandated reference standard.

— Societal perspective (general public valuing hypothetical states) — used by most HTA agencies, including NICE and ICER.

— Patient perspective (people with the condition) — often yields higher utilities because of adaptation; controversial.

— Large paired-comparison surveys in multiple countries (GBD methodology).

— Respondents choose which of two health states is "healthier" — weights are then statistically modeled.

— Not preference-based in the same utility-theoretic way as QALYs — this is a conceptual difference often tested.

— Some frameworks apply higher weight to QALYs gained by the disadvantaged (distributional cost-effectiveness analysis, DCEA).

— Addresses critique that standard QALYs are utilitarian and ignore distribution.

Board pearl: EQ-5D is the most commonly cited and tested utility instrument. If a stem says "researchers measured quality of life using a 5-domain questionnaire mapped to societal preference weights," the answer is EQ-5D generating QALYs.

How utility weights for QALYs are derived:

Whose preferences count?

How disability weights for DALYs are derived:

Equity weighting (proposed extensions):

Special Populations — Elderly and Disabled — Ethical Tensions

— A 30-year-old gaining one year of perfect health = 1 QALY.

— An 85-year-old gaining one year of perfect health = 1 QALY (same).

— But lifetime QALY gains favor younger patients because they have more years left → systematic age bias in cost-effectiveness rankings.

— A treatment that restores a disabled patient to their baseline disability (utility 0.5) cannot generate as many QALYs as the same treatment in an able-bodied patient returned to utility 1.0.

— Critics: this devalues lives of disabled persons in allocation decisions.

— ICER and NICE explicitly grapple with this; some frameworks adjust (severity modifiers, "fair innings" arguments).

— The Affordable Care Act prohibits CMS from using QALY thresholds to deny Medicare coverage (Section 1182) — driven by disability-rights advocacy.

— Some states (e.g., New York Medicaid, VA formulary) do use QALY-informed analyses.

— ICER publishes QALY-based assessments publicly, used by private payers.

Key distinction: The legal status of QALYs in US Medicare differs from their use in NICE (UK) and CADTH (Canada), both of which explicitly use cost-per-QALY thresholds for coverage decisions. A Step 3 stem set in CMS coverage context cannot use QALYs as a denial rationale; one set in UK NHS context can.

The elderly QALY problem:

The disabled QALY problem:

Renal/hepatic impairment analog: Not directly relevant to the math, but subgroup utilities must be carefully measured — patients on dialysis have utilities ~0.5–0.7, meaning interventions in this group may show smaller absolute QALY gains.

Practical US policy implications:

Special Populations — Pediatrics, Pregnancy, and Global Health

— A child's death generates the largest YLL because life expectancy from age 0 is greatest (~86 years in GBD reference) → child mortality dominates DALY rankings in LMICs.

— Pediatric utility elicitation is methodologically harder — proxy reports (parents) versus child-report instruments (EQ-5D-Y).

— Vaccines and child survival interventions (ORS, exclusive breastfeeding, ITN for malaria) consistently rank among the most DALY-efficient global interventions — pennies per DALY averted.

— Maternal mortality contributes large YLLs because deaths occur in young adulthood.

— Obstetric fistula, postpartum depression, eclampsia sequelae contribute substantial YLDs.

— Antenatal care, skilled birth attendance, magnesium for eclampsia, oxytocin for PPH are top-tier DALY-averting interventions globally.

— Leading global DALY causes: ischemic heart disease, stroke, neonatal disorders, lower respiratory infections, COPD, diabetes.

— Mental health and musculoskeletal disorders (depression, anxiety, low back pain) dominate YLDs but rarely cause death — historically under-prioritized.

— Epidemiologic transition: LMICs increasingly bear dual burden of communicable and non-communicable disease DALYs.

Board pearl: Low back pain and major depressive disorder are the perennial top-2 global causes of YLD — they contribute almost nothing to YLL but enormous disability burden. This is the classic example of why DALYs (not crude mortality) are needed for honest priority-setting.

Pediatric DALY/QALY considerations:

Pregnancy/maternal health:

Global Burden of Disease (GBD) headline findings (current, ~2019–2021 data) — high-yield:

COVID-19 impact: 2020–2022 GBD estimates showed COVID became a top-5 DALY cause globally, reversing decades of life-expectancy gains in some countries.

Complications — Methodological Pitfalls and Misuse

— Failure to discount future health → overestimates long-horizon prevention benefits.

— Using disease-specific life expectancy (rather than standard LE) for YLL → underestimates premature death burden.

— Ignoring comorbidity → double-counting YLDs when conditions co-occur (a patient with diabetes + depression should not have full disability weights added independently — multiplicative adjustment needed).

— Confusing prevalence-based and incidence-based YLD — incidence-based attributes lifetime burden to the year of onset; prevalence-based attributes burden to the years in which it occurs.

— Using inappropriate WTP threshold → e.g., applying $50,000/QALY (a 1990s figure) to modern US analyses.

— Aggregating QALYs across heterogeneous populations masks distributional inequities.

— Oregon Medicaid Prioritized List (1989–1990s) — early attempt to rank services by QALY-per-dollar — faced ADA discrimination complaints and was revised.

— Demonstrates that technical efficiency (max QALYs per dollar) can conflict with equity, rule of rescue, and disability rights.

— Industry-sponsored cost-utility analyses tend to report more favorable ICERs for sponsor products — Step 3 may test conflict-of-interest recognition.

— Different modeling choices (time horizon, comparator, perspective) can shift ICERs by orders of magnitude.

— Always report sensitivity analyses.

Key distinction: Cost-effective ≠ affordable. A drug with an ICER of $80,000/QALY may be deemed cost-effective but, if it must be given to 1 million patients, the budget impact may bankrupt the system. Modern HTA requires both ICER and budget impact analysis.

Pitfalls in DALY/QALY analysis that Step 3 may test as "what's wrong with this study":

Misuse for rationing:

Publication and modeling bias:

Uncertainty and model structure:

When to Escalate — Stakeholder and Decision Pathways

— Order: Request manufacturer rebate negotiation; budget-impact analysis; subgroup CEA in highest-benefit population; pilot with outcomes-based contract.

— Escalate to: P&T committee, payer contracting, ethics committee if access decisions affect vulnerable populations.

— FDA approves based on safety/efficacy — does not consider cost.

— CMS sets Medicare coverage — generally cannot use QALY thresholds (per ACA).

— ICER issues public value assessments — non-binding but influential on private payer policy.

— State Medicaid programs vary; some use ICER-style analyses.

— Private payers increasingly use ICER reports for formulary tiering and prior authorization.

— WHO-CHOICE: cost-effectiveness per DALY averted for global priority-setting.

— NICE (UK): ~£20,000–£30,000/QALY standard threshold, £50,000/QALY for end-of-life/cancer.

— CADTH (Canada), PBAC (Australia): similar cost-utility frameworks.

— Individual clinical decisions with shared decision-making → use patient-specific utilities, not population averages.

— Equity-focused decisions → consider distributional cost-effectiveness analysis (DCEA).

— Public emergencies → utilitarian QALY maximization may conflict with rule of rescue and identifiable-victim ethics.

Step 3 management: A question stem describing a hospital ethics consult for resource allocation during a crisis (e.g., ventilator triage) should pivot away from pure QALY maximization toward a multi-principle allocation framework (save most lives, save most life-years, lifecycle/age considerations, instrumental value), as articulated in pandemic ethics guidance.

CCS pearl (applied to a health-systems CCS-style case): "You are a CMO reviewing whether to adopt a new biologic. ICER reports $230,000/QALY. Next steps?"

Decision hierarchy in US health systems:

Global decision pathways:

When NOT to use cost-utility analysis (escalate to other frameworks):

Key Differentials — Same-Category Outcome Metrics

— Single number, easy to communicate.

— Ignores morbidity entirely.

— Insensitive to changes in adult mortality if child mortality dominates.

— Life expectancy adjusted for time spent in less-than-full health.

— Conceptually a QALY-style adjustment of LE.

— Used by WHO as a population summary alongside DALYs.

— Premature mortality before a cutoff age (commonly 65 or 75).

— Used by CDC for leading causes of premature death rankings.

— Cruder than YLL (no standard life table; just subtracts from a fixed cutoff).

— Captures mortality only — no morbidity.

— Lifetime expected QALYs at birth.

— Population-level QALY analog of life expectancy.

— Years expected to live without disability (binary disability state).

— Simpler than HALE; doesn't weight severity.

— Theoretical alternative to QALY using two-stage standard gamble.

— Rarely used in practice.

Key distinction: YPLL is to YLL what crude mortality is to age-adjusted mortality — YPLL uses an arbitrary cutoff (often 75), while YLL uses a model life expectancy at each age of death. CDC reports cite YPLL; WHO/GBD reports cite YLL. Stems mentioning "leading causes of premature death before age 75 in the US" want YPLL.

Life expectancy at birth (LE0):

Healthy Life Expectancy (HALE):

Years of Potential Life Lost (YPLL):

Quality-Adjusted Life Expectancy (QALE):

Disability-Free Life Expectancy (DFLE):

Healthy Years Equivalent (HYE):

Key Differentials — Other-Category Analytic Frameworks

— Monetizes all outcomes (health, lives) in dollars.

— Uses willingness-to-pay or value of statistical life (VSL ≈ $10 million in US) to monetize life.

— Allows comparison across non-health sectors (transportation, environment).

— Controversial because monetizing health is ethically charged.

— Used only when outcomes are equivalent between alternatives → choose cheapest.

— Rarely valid because outcomes are rarely identical.

— Lists costs and multiple outcomes separately without aggregation.

— Lets decision-makers weight outcomes themselves.

— Clinical metrics, not burden metrics — different question.

— Relate to efficacy, not burden of disease.

— Alternative to utilitarian QALY maximization.

— Focuses on capabilities (what people can do/be), not aggregated health.

— Less operational but increasingly influential ethically.

— Combines cost-effectiveness with equity, severity, unmet need, innovation.

— Used by some HTA agencies (e.g., Norway, Sweden) to address QALY limitations.

Board pearl: When a Step 3 stem describes a public transportation safety investment being compared to a screening program, only cost-benefit analysis (with dollarized outcomes) can compare them. Cost-utility (QALYs) compares only health interventions; cost-benefit compares across any sectors.

Cost-benefit analysis (CBA):

Cost-minimization analysis (CMA):

Cost-consequence analysis (CCA):

Number needed to treat (NNT) and absolute risk reduction (ARR):

Disability-rights / capabilities approach (Sen, Nussbaum):

Multi-criteria decision analysis (MCDA):

Secondary Prevention — Applying QALY Logic to Long-Term Care

— Statins after MI: ICER often dominant (cost-saving) due to recurrent event prevention.

— ACE inhibitors in HFrEF: ICER < $20,000/QALY — extremely cost-effective.

— Beta-blockers post-MI: cost-saving in most analyses.

— Dual antiplatelet therapy post-PCI: cost-effective at 12 months; beyond 12 months, marginal.

— Cardiac rehabilitation post-MI: ICER < $50,000/QALY plus QoL gains.

— DPP-4 vs SGLT2 vs GLP-1 in T2DM: SGLT2 and GLP-1 are increasingly favored on QALY grounds in patients with CV/renal disease despite higher drug cost.

— Smoking cessation counseling + pharmacotherapy: often dominant (cost-saving and QALY-gaining).

— Colorectal cancer screening (FIT, colonoscopy): ICER $10,000–$30,000/QALY.

— HPV vaccination: cost-saving in most analyses.

— Low-cost, modest QALY gains, low ICER — favored in value-based care.

— Interventions that prevent disabling sequelae (stroke, heart failure, ESRD) generate large QALY gains via YLD reduction, not just YLL reduction.

— Frame patient counseling around lifetime expected QALYs, not just risk reduction percentages — more concrete for shared decision-making.

Step 3 management: On discharge from an MI admission, the highest-QALY-impact orders are guideline-directed medical therapy (statin, BB, ACEi/ARB, DAPT), smoking cessation, cardiac rehab referral, and blood pressure / lipid follow-up at 4–6 weeks. Omitting any of these forfeits substantial QALYs at minimal cost.

Many of the most QALY-favorable interventions in US practice are secondary prevention measures — high-yield to recognize on Step 3:

Discharge medication reconciliation and patient education:

Long-term plan logic:

Follow-Up, Monitoring, and Counseling Through a QALY Lens

— Track DALY trends over time to assess program effectiveness (e.g., did smoking cessation funding reduce tobacco DALYs?).

— Stratify DALYs by subpopulation (income, race, geography) to identify health inequities.

— Use YLD/YLL ratio to detect shifts: rising YLD share signals epidemiologic transition to chronic disease dominance.

— In oncology and chronic disease, patient-reported outcome measures (PROMs) like EQ-5D and PROMIS feed directly into QALY estimation.

— Routine PROM collection enables real-world QALY surveillance of therapies post-approval.

— Cardiac rehab, pulmonary rehab, stroke rehab, oncology survivorship — all designed to raise utility weights during chronic survival, directly increasing QALYs.

— Mental health integration (collaborative care for depression) yields 0.05–0.10 utility gains, translating to meaningful QALYs over years.

— Translate ICERs into patient-friendly language: "This medication adds about 6 quality-adjusted months over 10 years."

— Avoid implying that patients with low utilities have "less valuable" years — frame in terms of gains achievable.

— Post-MI: 1–2 weeks (medication tolerance), 4–6 weeks (lipid/BP), 3 months (cardiac rehab progress), then 6–12 months.

— Each touchpoint is an opportunity for utility-improving interventions (titration, depression screening, exercise prescription).

Board pearl: Collaborative care models for depression in chronic disease (e.g., post-MI, diabetes) consistently demonstrate ICERs under $20,000/QALY — a Step 3-favored answer when asked the most cost-effective addition to chronic disease management with comorbid depression.

Population health monitoring using DALY/QALY frameworks:

Patient-level monitoring:

Rehabilitation focus:

Counseling content:

Follow-up cadence examples:

Ethical, Legal, and Patient Safety Considerations

— QALY-based allocation systematically yields fewer QALYs gained per intervention in disabled or chronically ill patients (lower baseline utility, ceiling effect).

— US ACA Section 1182 explicitly bars CMS from using QALY thresholds to deny coverage — a direct legislative response to disability-rights advocacy.

— Step 3 may test: "A Medicare beneficiary is denied a cancer therapy on the basis that ICER exceeds $200,000/QALY. Is this legal?" → No, under current US Medicare statute.

— Pure lifetime-QALY maximization favors the young; "fair innings" arguments support some weighting toward those who have had fewer years.

— Pandemic ventilator triage protocols explicitly grapple with this.

— When using utility-based decision aids, patients must understand that utility weights reflect societal averages that may not match their personal values.

— A patient may rationally choose a lower-QALY option that aligns with their preferences (e.g., quality-of-life-preserving palliative care over aggressive treatment).

— A patient discharged on a QALY-favorable regimen (e.g., GDMT for HFrEF) but without medication reconciliation, follow-up scheduled within 7 days, and PCP communication loses much of the projected QALY benefit — a documented patient-safety failure mode.

— Hospital readmission penalties (CMS HRRP) are partly justified by the QALY losses associated with avoidable readmissions.

— Public health DALY/YLL tracking depends on complete cause-of-death reporting — under-reporting (e.g., opioid overdoses miscoded) distorts national priorities.

— Clinicians have a duty to accurate death certification as a population-health safety obligation.

— Industry-funded CEAs require disclosure; reviewers should scrutinize assumptions about utility weights and comparator choice.

Key distinction: In the US, QALYs may inform payer and clinical decisions but cannot be the sole basis for Medicare coverage denials. This legal-ethical boundary is testable.

Discrimination concerns:

Age discrimination:

Informed consent in QALY-informed decisions:

Transition-of-care risk (Step 3 favorite):

Mandatory reporting and surveillance:

Conflict of interest:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When in doubt on a US Step 3 stem about which metric to use for comparing two different diseases' interventions, choose cost-utility analysis with QALYs. For comparing two interventions targeting the same outcome, cost-effectiveness analysis with natural units (life-years, cases prevented) suffices.

DALY = YLL + YLD. Memorize this equation.

QALY = Σ (time × utility). Memorize this equation.

Disability weight: 0 = perfect health, 1 = death. Utility weight: 0 = death (or worse), 1 = perfect health. They are inversely scaled.

Standard discount rate: 3%/year for both costs and health outcomes (US convention).

US WTP threshold: $100,000–$150,000/QALY (modern); historical $50,000.

NICE (UK) threshold: £20,000–£30,000/QALY; up to £50,000/QALY for end-of-life.

WHO-CHOICE: very cost-effective if <1× per capita GDP/DALY; cost-effective if <3× GDP/DALY (though WHO has moved away from rigid thresholds).

Top global DALY causes (current GBD): ischemic heart disease, stroke, neonatal disorders, LRIs, COPD.

Top global YLD causes: low back pain, depression, headache disorders, anemia, diabetes.

GBD reference life expectancy: ~86 years (current).

EQ-5D: 5 domains (mobility, self-care, usual activities, pain, anxiety/depression); standard QALY instrument.

Standard gamble = theoretical gold standard for utility elicitation; TTO is most practical; VAS is biased.

ICER formula: ΔCost / ΔQALY.

Cost-saving dominance: less costly AND more effective → adopt immediately.

Dominated: more costly AND less effective → reject.

Most cost-effective US interventions historically: childhood vaccination, smoking cessation counseling, statins in secondary prevention, aspirin in secondary prevention, BP control.

Oregon Medicaid Prioritized List: classic case of QALY-based rationing meeting disability-rights pushback.

ACA Section 1182: bars CMS QALY-based denial.

Sensitivity analysis: required for credible CEA/CUA.

Markov model: standard structural framework for chronic disease cost-utility modeling.

Board Question Stem Patterns

Step 3 management: Match the denominator to the question: across diseases in the US → $/QALY; across diseases globally → $/DALY averted; within a disease across two drugs → $/life-year gained or $/event prevented.

Stem 1 — Definition recognition: "A composite measure summing years of life lost to premature death and years lived with disability is called…" → DALY.

Stem 2 — Calculation: "A patient lives 4 years at 0.75 utility, then 2 years at 0.4. How many QALYs?" → (4 × 0.75) + (2 × 0.4) = 3.8 QALYs.

Stem 3 — ICER: "Drug A costs $30,000 more and gains 0.5 QALYs vs standard. ICER?" → $60,000/QALY — cost-effective in US.

Stem 4 — Framework selection: "Compare HPV vaccination vs colonoscopy screening. Best metric?" → Cost per QALY gained (cost-utility, comparing across diseases).

Stem 5 — Discounting: "Why does a childhood vaccination program have a less favorable ICER than expected?" → Future QALYs discounted at 3%/year.

Stem 6 — Top causes: "Leading global cause of years lived with disability?" → Low back pain (or major depressive disorder, depending on year).

Stem 7 — Legal: "Can CMS deny coverage of a $500,000/QALY drug based on cost-effectiveness alone?" → No (ACA Section 1182).

Stem 8 — Methodology: "A study uses EQ-5D to derive weights for a cost analysis. What outcome metric?" → QALY.

Stem 9 — Dominance: "Drug B is cheaper and more effective than Drug A. What is Drug A?" → Dominated.

Stem 10 — Equity critique: "Why might disability-rights advocates oppose QALY-based allocation?" → Disabled patients can gain fewer QALYs because of lower baseline utility, leading to systematic deprioritization.

Stem 11 — Distinguishing metrics: "What is the difference between YPLL and YLL?" → YPLL uses fixed cutoff age (e.g., 75); YLL uses standard life expectancy at age of death.

Stem 12 — Public health priority: "WHO compares malaria treatment vs maternal mortality reduction. Best metric?" → DALYs averted per dollar.

One-Line Recap

DALYs and QALYs are composite population health metrics that integrate mortality and morbidity — DALYs (= YLL + YLD) measure health lost and dominate global burden-of-disease and WHO priority-setting, while QALYs (= time × utility) measure health gained and dominate cost-utility analysis and HTA decisions in high-income health systems.

Board pearl: If you remember nothing else: DALY = bad years (lower better); QALY = good years (higher better); ICER = $/QALY = price tag for one extra year of perfect health.

Core equations: DALY = YLL + YLD; QALY = Σ(duration × utility weight); ICER = ΔCost/ΔQALY.

Scale direction: disability weight 0 (healthy) → 1 (death); utility weight 0 (death) → 1 (healthy) — inverted, the #1 confusion point.

US context: $100K–$150K/QALY is the cost-effectiveness band; ACA Section 1182 bars CMS from using QALYs to deny Medicare coverage; ICER publishes influential public assessments.

Global context: GBD reports rank diseases by DALYs; ischemic heart disease and stroke top global DALY rankings; low back pain and depression top global YLD rankings — a powerful argument that crude mortality alone misses half the burden of disease.

Critiques to know: age and disability bias inherent in QALY maximization, sensitivity to discount rate, dependence on whose preferences supply the weights, and the ethical limits of pure utilitarian aggregation — addressed via distributional CEA, severity modifiers, and multi-criteria decision analysis.

Step 3 framing: choose cost-utility (QALYs) for cross-disease comparisons in US/HIC settings; cost-effectiveness (natural units) for same-disease comparisons; DALYs for WHO/global priority-setting; cost-benefit (dollars) when comparing health to non-health sectors.